# Real-world multicenter study of rezvilutamide plus androgen deprivation therapy in Chinese patients with high-volume metastatic hormone-sensitive prostate cancer

## TL;DR

This study shows that rezvilutamide plus ADT is effective and safe for Chinese patients with high-volume metastatic hormone-sensitive prostate cancer.

## Contribution

The study provides real-world evidence from China on rezvilutamide plus ADT for high-volume metastatic hormone-sensitive prostate cancer.

## Key findings

- 99.15% of patients achieved PSA50, 88.98% achieved PSA90, and 39.41% achieved PSA ≤0.2 ng/mL at 3 months.
- Baseline PSA was a predictor of achieving undetectable PSA levels, though not statistically significant in multivariable analysis.
- Adverse events were consistent with previous trials, with no new severe safety signals observed.

## Abstract

Rezvilutamide combined with androgen deprivation therapy (ADT) has become a first-line standard regimen for high-volume metastatic hormone-sensitive prostate cancer (mHSPC), but real-world evidence from China remains limited.

This was a multicenter, retrospective real-world cohort study enrolling high-volume mHSPC patients diagnosed and treated with rezvilutamide plus ADT at multiple tertiary hospitals in China from August 2023 to March 2025. Baseline demographics, tumor burden, treatment regimen, and follow-up data were collected. The primary endpoints were 3-month PSA responses (PSA50, PSA90, PSA ≤0.2 ng/mL), subgroup efficacy, and adverse event rates. Multivariable logistic regression was used to identify independent predictors for achieving PSA ≤0.2 ng/mL at 3 months. Efficacy and safety outcomes were compared with major randomized controlled trials (RCTs) and other real-world studies.

A total of 236 patients with high-volume mHSPC were enrolled, with a median age of 74.9 years. The rates of achieving PSA50, PSA90, and PSA ≤0.2 ng/mL at 3 months were 99.15%, 88.98%, and 39.41%, respectively. Subgroup analysis showed consistent efficacy across age, ECOG, and Gleason strata, with only lower baseline PSA predicting higher likelihood of undetectable PSA. Multivariable analysis further indicated that baseline PSA showed a trend toward being an independent predictor for achieving PSA ≤0.2 ng/mL (P=0.063). The incidence of any-grade and grade 3–4 adverse events was 65% and 23%, respectively, with no new severe safety signals observed. All results were highly consistent with RCTs such as CHART.

Rezvilutamide plus ADT provides rapid and profound PSA responses with a favorable safety profile in real-world Chinese patients with high-volume mHSPC. Baseline PSA serves as an important predictor for short-term biochemical response, supporting its clinical value as a standard first-line therapy.